The American Society of Clinical Oncology (ASCO) endorsed the joint College of American Pathologists (CAP)/International Association for the Study of Lung Cancer (IASLC)/Association for Molecular Pathology (AMP) clinical practice guideline on EGFR and ALK molecular testing for patients with lung cancer, which holds that an ALK fluorescent in-situ hybridization (FISH) assay using dual-labeled break-apart probes is the preferred testing methodology to detect ALK gene rearrangement [12]. The gene discussed is ALK; the disease is lung cancer.